Morgan Stanley Maintains Buy Rating on Bicara (BCAX) After the Ficerafusp Alfa Trial Update

On May 23, Judah Frommer from Morgan Stanley maintained a Buy rating on Bicara Therapeutics Inc. (NASDAQ:BCAX) while keeping the price target at $36.

This comes after the company released its interim data from Phase 1/1b trial of Ficerafusp alfa, which is the company’s lead asset and a first-in-class bifunctional antibody.

Close-up of a scientist in a lab conducting tests on a humanized immunoglobulin G1.

Bicara Therapeutics Inc. (NASDAQ:BCAX) is a clinical-stage biopharmaceutical company that develops innovative bifunctional antibody therapies for solid tumors. Ficerafusp alfa is being tested for enhanced tumor penetration and to overcome the immunosuppressive tumor microenvironment, which has historically limited treatment efficacy in solid tumors.

The recent data from the Phase 1/1b study has shown promising results in treating HPV-negative patients who have head and neck squamous cell carcinoma. The analyst highlighted that the trial reported a median overall survival exceeding 20 months, including an 18-21% complete response rate. Frommer believes this is a significant improvement compared to standard care, suggesting that approval of Ficerafusp alfa could be a breakthrough in a challenging therapeutic area.

While we acknowledge the potential of BCAX as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than BCAX and that has 100x upside potential, check out our report about the cheapest AI stock.

READ NEXT: 11 Most Promising New Technology Stocks According to Analysts and 12 Best Growth Stocks to Buy and Hold for the Long Term.

Disclosure: None.